ARTICLE | Finance
Vivo-led $105M round to spur development of ALX’s CD47
Vivo thinks ALX’s CD47-targeted cancer therapy could be best in class thanks to its safety profile
February 13, 2020 1:31 AM UTC
Updated on Mar 4, 2020 at 12:56 AM UTC
Encouraged by safety data for ALX’s CD47-targeted cancer therapy, Vivo Capital led the biotech’s $105 million series C Wednesday to fuel its clinical catch-up to its most advanced competitor.
Other new investors including funds managed by Logos Capital, Janus Henderson, Foresite Capital, Cormorant Asset Management, BVF Partners and HBM Healthcare Investments participated in the untranched financing, as did existing investors venBio and Lightstone Ventures...
BCIQ Target Profiles